Headache prevalence in transgender and gender diverse youth: A single-center case-control study

被引:4
|
作者
Hranilovich, Jennifer A. [1 ]
Millington, Kate [2 ,3 ]
机构
[1] Univ Colorado, Dept Pediat, Div Child Neurol, Sch Med, Aurora, CO 80045 USA
[2] Hasbro Childrens Hosp, Dept Pediat, Div Endocrinol, Providence, RI USA
[3] Brown Univ, Warren Alpert Med Sch, Dept Pediat, Providence, RI USA
来源
HEADACHE | 2023年 / 63卷 / 04期
关键词
adolescent; headache; hormone; transgender; SEX-DIFFERENCES; GLOBAL BURDEN; MIGRAINE; BRAIN; TRANSSEXUALS; PAIN;
D O I
10.1111/head.14493
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective Assess the prevalence of headache in transgender and gender-diverse adolescents, comparing prevalence with and without exposure to gender-affirming hormone therapy.Background Transgender and gender-diverse youth are an understudied group in whom we can study the effects of sex steroids on adolescents' development of headache. We hypothesized that transfeminine adolescents treated with estrogen would have higher odds of headache than those not treated, and that transmasculine adolescents treated with testosterone would have lower odds of headache than those not treated.Methods This retrospective case-control study analyzed all patients seen at the Boston Children's Hospital Gender Multispecialty Service clinic from 2007 to 2017. Cases were defined as patients with headache, controls as those without headache, and exposure as treatment with gender-affirming hormone therapy (i.e., estrogen or testosterone). A computerized search identified cases that were then validated by chart review.Results Fifty-two of the 763 transgender and gender-diverse patients seen were confirmed to have headache. Of 273 transfeminine patients 45% (123/273) received estrogen treatment. Transfeminine patients receiving estrogen were more likely to have headache than those not receiving estrogen (7% [9/123] vs. 1% [2/150]; odd ratio [OR] 5.84 (95% confidence interval [CI] 1.24-27.6), p = 0.026). Of 490 transmasculine patients, 46% (227/490) received testosterone. Transmasculine patients receiving testosterone were more likely to have headache than those not receiving testosterone (12% [28/227] vs. 5% (13/263); OR 2.71 (95% CI 1.37-5.4), p = 0.005).Conclusion Among transfeminine and transmasculine youth, those who received gender-affirming hormone therapy had higher odds of headache compared to those not taking gender-affirming hormone therapy. Further prospective studies to guide headache care of transgender and gender-diverse youth and adults are needed. Our results could be generalizable to other pediatric gender management clinics and may be worth discussing with patients considering treatment.
引用
收藏
页码:517 / 522
页数:6
相关论文
共 50 条
  • [1] Prevalence of Coagulopathy in Patients with Celiac Disease: A Single-Center Retrospective Case-Control Study
    Balaban, Daniel Vasile
    Coman, Laura Ioana
    Enache, Iulia Cristina
    Mardan, Cristian Mihail
    Dima, Alina
    Jurcut, Ciprian
    Balaban, Marina
    Costache, Raluca Simona
    Ionita-Radu, Florentina
    Popp, Alina
    Jinga, Mariana
    GASTROENTEROLOGY INSIGHTS, 2023, 14 (04) : 463 - 474
  • [2] INCREASED RATE OF PANCREATITIS IN GENDER DIVERSE AND TRANSGENDER PATIENTS ON HORMONE THERAPY: A CASE-CONTROL STUDY
    Podboy, Alexander J.
    Casey, Catherine F.
    Radlinski, Mark J.
    Sauer, Bryan G.
    Buerlein, Ross C.
    Strand, Daniel S.
    Shami, Vanessa M.
    Wang, Andrew Y.
    GASTROENTEROLOGY, 2023, 164 (06) : S969 - S969
  • [3] Depression and anxiety in systemic lupus erythematosus: A case-control study on prevalence and associated factors in a single-center cohort
    Leon-Suarez, Paola
    Rua-Figueroa, Inigo
    Gonzalez Martin, Jesus
    Rodriguez-Sosa, Teresa
    Erausquin, Celia
    Almeida Santiago, Cristina del Pino
    Rubino Juarez, Francisco
    Perez Vera, Yanira
    Caceres Martin, Laura
    Lopez Sanchez, Ruben
    Quevedo Abeledo, Juan Carlos
    Francisco Hernandez, Felix
    Ojeda Bruno, Soledad
    Naranjo Hernandez, Antonio
    Quevedo Rodriguez, Adrian
    Rodriguez Lozano, Carlos
    LUPUS, 2023, 32 (07) : 827 - 832
  • [4] An insight into Clostridium difficile infection: a single-center retrospective case-control study
    Haddad, Fady G.
    Zaidan, Julie
    Polavarapu, Abhishek
    Khan, Hafiz
    Khan, Asif
    Mudduluru, Bindu Madhavi
    Saabiye, Joseph
    Lukanovic, Slobodanka
    Demissie, Seleshi
    Mulrooney, Stephen
    Khalil, Ambreen
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (10): : 1183 - 1195
  • [5] Pregnancy-Associated Ovarian Torsion - a Single-Center Case-Control Study
    Meyer, Raanan
    Meller, Nir
    Amitai Komem, Daphna
    Abu-Bandora, Eiman
    Cohen, Adiel
    Cohen, Shlomo B.
    Mashiach, Roy
    Levin, Gabriel
    REPRODUCTIVE SCIENCES, 2023, 30 (06) : 1998 - 2002
  • [6] Is damage control surgery useful in the treatment of colorectal perforation? A single-center case-control study
    Kunitatsu, Kosei
    Ueda, Kentaro
    Nasu, Toru
    Kawashima, Shuji
    Okishio, Yuko
    Kato, Seiya
    ANNALS OF MEDICINE AND SURGERY, 2023, 85 (04): : 645 - 649
  • [7] Case report: Hilar metastasis of breast cancer: A single-center retrospective case-control study
    Yang, Ruohan
    Jia, Lin
    Lv, Zheng
    Cui, Jiuwei
    FRONTIERS IN SURGERY, 2023, 10
  • [8] Demographic and Epidemiological Factors Associated with Eosinophilic Colitis: A Single-Center, Case-Control Study
    Winters, Harry
    Ward, Amanda
    Nguyen Pham
    GASTROENTEROLOGY, 2016, 150 (04) : S894 - S894
  • [9] Development and validation of the prediction models for preeclampsia: a retrospective, single-center, case-control study
    Chen, Xuhong
    Yuan, Li
    Ji, Zhen
    Bian, Xiyun
    Hua, Shaofang
    ANNALS OF TRANSLATIONAL MEDICINE, 2022,
  • [10] Comorbidities of bullous pemphigoid: A single-center retrospective case-control study from Turkey
    Sayar, Sila Kilic
    Sun, Gizem Pinar
    Kucukoglu, Rifkiye
    DERMATOLOGIC THERAPY, 2021, 34 (05)